Skip to content

    Anupam Rasayan India Limited

    ANURAS
    Chemicals·14 Feb 2026
    Management Summary

    Anupam Rasayan reported strong financial performance for Q3 and 9MFY26, driven by commercial molecule scale-up and improved capacity utilization. The company announced the strategic acquisition of Jayhawk Fine Chemicals, aiming to expand its global footprint and access high-value end markets. Segmental growth was robust, particularly in Pharma and Performance Material, contributing to a diversified revenue mix.

    Highlights

    5
    • Consolidated revenue for 9MFY26 grew 84% year-on-year to INR1,730 crores.

    • EBITDA for 9MFY26 increased 53% year-on-year to INR402 crores, with a 23% margin.

    • PAT for 9MFY26 registered 71% year-on-year growth to INR166 crores.

    • Q3 FY26 revenue grew 31% year-on-year to INR512 crores, with an EBITDA margin of 25%.

    • Acquisition of Jayhawk Fine Chemicals will provide direct onshore manufacturing presence in the US, enhance access to high-value end markets, and is expected to be EPS accretive from day one.

    Key financials

    Metrics

    8

    Periods

    2

    Headline

    4
    • 9MFY26 Revenue
      ₹1,730 Cr
      YoY+84%
    • 9MFY26 EBITDA
      ₹402 Cr
      YoY+53%
    • 9MFY26 PAT
      ₹166 Cr
      YoY+71%
    • 9MFY26 EBITDA Margin
      23%

    Q3 FY26

    4
    • Revenue
      ₹512 Cr
      YoY+31%
    • EBITDA
      ₹130 Cr
    • PAT
      ₹61 Cr
      YoY+12%
    • EBITDA Margin
      25%

    Segment breakdown

    Pharma
    19% Contribution to 9MFY26 Sales85% 9MFY26 YoY Growth
    Performance Material
    17% Contribution to 9MFY26 Revenue2.5% 9MFY26 YoY Growth
    Japan Revenue
    17% Contribution to Q3 Revenue
    Exports
    58% Contribution to Total Revenue
    List

    Capital allocation

    1
    high confidence
    CategoryHeadline
    M&A

    Jayhawk Fine Chemicals

    acquisition · signed

    Guidance & targets

    2
    CategoryTargetPriority
    Working Capital
    Working Capital Days
    220-200 days
    Medium
    Working Capital
    Working Capital Days
    below 200, around 180 days or below
    High

    What to watch in Q4 FY26

    4

    Jayhawk acquisition closing and financial impact

    next quarter
    CurrentSigned definitive agreement, expected to close in coming weeks.
    TargetAcquisition closed, financial contribution reflected in next quarter's results.

    Why it matters

    The acquisition is strategic and expected to be EPS accretive, so its timely closure and initial financial contribution are key for growth.

    We are currently in the process of completing the formalities of the acquisition and expect it to be closed in the coming weeks. ... we expect the acquisition to be EPS accretive from day one. ... we shall be then adding it to the next quarter's numbers appropriately.

    0

    Q&A highlights

    5

    “So right now, we have not yet consolidated the numbers as the transaction is yet to be completed. And hence, no contribution of the Jayhawk's revenue or profit has been added to this quarter's results or the nine-month result that we have announced. And going forward, once we conclude this transaction, which we are expecting as Anand Bhai said over next a week or two or couple of weeks, we shall be then adding it to the next quarter's numbers appropriately.”

    Clarifies that the financial impact of the acquisition will be reflected in future quarters, not the current reported period.

    asked by Tanya Chowdhary

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Financial Performance in Q3 and 9MFY26

    Anupam Rasayan reported robust financial results for the quarter and nine months ended December 31, 2025. For 9MFY26, consolidated revenue reached INR1,730 crores, marking an 84% year-on-year growth. EBITDA stood at INR402 crores, up 53% YoY, with a healthy margin of 23%. PAT for the nine-month period grew 71% YoY to INR166 crores. In Q3 FY26 alone, revenue was INR512 crores, a 31% increase YoY, and EBITDA was INR130 crores, translating to a 25% margin.

    02

    Strategic Acquisition of Jayhawk Fine Chemicals

    The company signed a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals company. This acquisition is pivotal for establishing a direct onshore manufacturing presence in the US, enhancing engagement with multinational customers, and expanding into high-growth end markets such as semiconductors, EV, and Pharma. Management expects the acquisition to be EPS accretive from day one and anticipates closing the transaction in the coming weeks, with financial consolidation in the next quarter.

    03

    Diversified Segmental Growth and Product Pipeline

    Anupam Rasayan's revenue mix is well-diversified across Agro, Pharma, Personal Care, and Performance Material segments. The Pharma segment contributed 19% of sales for 9MFY26, growing 85% YoY, driven by import substitution and new product additions. The Performance Material segment, including defense and electronic materials, showed exceptional growth of 245% YoY in 9MFY26, contributing 17% to total revenue. The company's R&D pipeline remains strong with over 65 molecules in Pharma and Polymer/Electronic Material verticals.

    04

    Focus on Supply Chain Resilience and Customer Engagement

    The company emphasizes strengthening its supply chain, with the Tanfac acquisition in 2022 providing uninterrupted access to critical raw materials like HF and KF for fluorination chemistry. This focus extends to the Jayhawk acquisition, which will further enhance supply chain offerings to US customers. Exports contributed 58% of total revenue, reaffirming a strong global presence. Japan, in particular, contributed almost 17% to Q3 revenue, driven by increasing engagement and new customers.

    05

    Working Capital Management and Future Outlook

    Management noted that working capital intensity for the consolidated entity is currently around 250 days. The company aims to reduce this to 220-200 days in the near-term and further to below 200 or around 180 days by FY27. Anupam Rasayan remains optimistic about sustaining growth momentum into the next fiscal year, supported by pipeline visibility, deeper customer relationships, and expanding global footprints.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.